GOLDEN, Colo. — December 13, 2022 — PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with
View
GOLDEN, Colo. — November 29, 2022 — PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced they received an $800,000+ direct to Phase II grant from the National Institutes of Health (NIH), to evaluate the immunogenicity of intradermal administration
View
GOLDEN, Colo. — November 8, 2022 — PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their PharmaJet Tropis® Needle-free Injection System (NFIS) will be used in a door-to-door immunization campaign aimed at reducing the outbreak of circulating
View
GOLDEN, Colo. — October 24, 2022 — PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced they received a multi-year, $1.5 million grant from the United States Agency for International Development (USAID), to evaluate the impact of intradermal (ID)
View
GOLDEN, Colo. — September 27, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their latest research results will be presented at five upcoming conferences in October:
View
GOLDEN, Colo. — September 12, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the Military Health System Research Symposium (MHSRS) on September 13, 2022. The presentation, entitled
View
GOLDEN, Colo. — August 31, 2022 — PharmaJet® , a company who has developed and commercialized an intradermal needle-free platform to more effectively administer drugs and biologics, today announced that the World Health Organization (WHO) selected the PharmaJet Tropis® Needle-free Injection System (NFIS) for large polio vaccination campaigns in Pakistan
View
GOLDEN, Colo. — August 16, 2022 — PharmaJet® , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection
View
GOLDEN, Colo. — August 2, 2022 — PharmaJet® , a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2
View
Load more